Recent Finacing
Recent Raise
Apellis is a clinical-stage biopharmaceutical company developing C3-targeted complement inhibitors, including PEG-conjugated APL-2, in clinical trials for retinal disease, PNH, COPD, and other autoimmune/inflammatory conditions.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors